Israel state records י"ג בשבט התשס"ח January 20, 2008

שימוש בליגנד flt3 ליצור תכשירים להגברת תגובה חיסונית ותכשירים המכילים אותם	USE OF FLT3-LIGAND FOR THE PRODUCTION OF COMPOSITIONS FOR AUGMENTING AN IMMUNE RESPONSE AND COMPOSITIONS COMPRISING SAME
[54]
	03.10.1996					[22]
	US	[33]	04.10.1995	[32]	08/539142	[31]
Int. Cl.8 A61K 035/12, 038/18, 039/00, 039/39, A61P 031/00, 031/18, 035/00, 037/04, 037/06, 043/00, C07K 014/52, C12N 005/06, 005/22						[51]
			IMMUNEX CORPORATION, U.S.A.			[71]
	WO/1997/012633					[87]
ריינהולד כהן ושותפיו, רחוב אחד העם 21 , ת.ד. 4060, תל אביב			REINHOLD COHN AND PARTNERS, 21 AHAD HA'AM ST., P.O.B. 4060, TEL AVIV 61040			[74]

[57] Use of flt3-ligand for the production of a pharmaceutical composition for augmenting an immune response in a patient, the amount o flt3-ligand being sufficient to obtain an increase in the number of dendritic cells in said patient.

__________

125912			[21][11]
תכשיר עיניים מקומי המכיל מעכב קרבוניק אנהידראז לטפול באדמה של המקולה ודגנרציה של המקולה הקשורה בגיל			TOPICAL OPHTHALMIC COMPOSITION CONTAINING A CARBONIC ANHYDRASE INHIBITOR FOR TREATING MACULAR EDEMA AND AGE-RELATED MACULAR DEGENERATION			[54]
	25.02.1997					[22]
	US	[33]	26.02.1996	[32]	60/012250	[31]
	GB		18.03.1996		9605642.9
Int. Cl.8 A61K 031/335, 031/38, 031/395, 031/542, 045/00, A61P 027/02, C07D 209/30, 307/82						[51]
			INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION, U.S.A.			[71]
	WO/1997/030704					[87]
איתן, פרל, לצר וכהן צדק, רחוב שנקר 7 , ת.ד. 12688, הרצליה			EITAN, PEARL, LATZER AND COHEN ZEDEK, P.O.B. 12688, HERZLIYA 46733			[74]

[57] Use of carbonic anhydrase inhibitor in sufficient amounts in the preparation of a medicament for topical administration to the eye, for treating and preventing macular edemas and age-related macular degeneration.

__________

126395			[21][11]
תכשירים המכילים פוליפפטידי הימוגלובין ושימושם			COMPOSITIONS CONTAINING HEMOGLOBIN POLYPEPTIDES AND USES THEREOF			[54]
	03.04.1997					[22]
	US	[33]	03.04.1996	[32]	08/627173	[31]
Int. Cl.8 A61K 038/00, 038/16, 038/42, A61P 035/00, 037/00, 043/00, C07K 005/08, 005/10, 007/06, 014/00, 014/47, 014/475, 014/52, 014/805						[51]
			WELLSTAT THERAPEUTICS CORPORATION, U.S.A.			[71]
			STEPHEN D. WOLPE, IRENA TSYRLOVA			[72]
	WO/1997/036922					[87]
ירמיהו מ. בן-דוד ושות' בע"מ, רחוב המרפא, הר חוצבים , ת.ד. 45087, ירושלים			JEREMY M. BEN-DAVID & CO. LTD., HAR HOTZVIM HI-TECH PARK, P.O.B. 45087, JERUSALEM 91450			[74]

[57] A polypeptide consisting of amino acids 1-97 of the human alpha hemoglobin chain, either alone, or in admixture with a polypeptide consisting of amino acids 1-94 of the human alpha hemoglobin chain, wherein the corresponding full-length human alpha hemoglobin chain is shown in Figure 16A as shown in the specification and a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the polypeptide or admixture.

בקשות חלוקה מבקשה זו שטרם פורסמו.		176642,159708,		The applications for division from this application have not yet been published

__________

126970			[21][11]
שימוש באינטרפרון להכנת תכשיר רוקחי לטיפול בגידולים			USE OF INTERFERON FOR THE PREPARATION OF MEDICAMENTS FOR THE TREATMENT OF NEOPLASTIC CONDITIONS			[54]
	05.05.1997					[22]
	AU	[33]	09.05.1996	[32]	PN9765	[31]
Int. Cl.8 A61K 038/21, A61P 035/00, C07K 014/555						[51]
			PHARMA PACIFIC PTY. LTD., AUSTRALIA			[71]
	WO/1997/041886					[87]
ריינהולד כהן ושותפיו, רחוב אחד העם 21 , ת.ד. 4060, תל אביב			REINHOLD COHN AND PARTNERS, 21 AHAD HA'AM ST., P.O.B. 4060, TEL AVIV 61040			[74]

[57] Use of interferon for the preparation of a medicament for oromucosal contact to treat a neoplastic condition in a mammal which medicament comprises a therapeutically effective amount of the interferon, said amount being from 5000 IU to 20x10⁶ IU, said amount being less than an amount which induces a pathological response in the mammal when administered parenterally.

__________

127641		[21][11]
מתקן ושיטות לטיפול אלקטרומגנטי רפואי		ELECTROMAGNETIC THERAPEUTIC TREATMENT DEVICE AND METHODS OF USING SAME	[54]
	19.06.1996		[22]
Int. Cl.8 A61N 001/00			[51]
		ROBERT R. HOLCOMB, U.S.A.	[71]
	WO/1997/000639		[87]
ד"ר מרק פרידמן בע"מ, מגדל משה אביב, ק.54 , רח ז'בוטינסקי 7, רמת- גן		DR. MARK FRIEDMAN LTD., MOSHE AVIV TOWER, 54TH FLOOR, 7 JABOTINSKY ST., RAMAT GAN 52520	[74]

[57] A therapeutic electromagnetic treatment device (10) adapted for placement against the bodies of living animals comprising: a plurality of electromagnetic bodies comprising at least four electromagnetic bodies (18, 20, 22, 24) each having at least one magnetic pole lying substantially in a single plane as a magnetic pole of each of the other electromagnetic bodies; containment means for holding said magnetic poles which lie substantially in the same plane in an orientation in which they define the four vertices of a quadrilateral shape, each of said magnetic poles exerting a magnetic force on the other three poles when said poles are electrically charged; power supply means (14) for magnetically energizing said electromagnetic bodies such that said energized electromagnetic bodies each generate a magnetic flux field, whereby said magnetic poles energized together form a flux generator head (12) which generates a flux field with a sharp three dimensional gradient; and a ferroconductor flux return ring (16a) bolted to the end of the pole which faces away from the animal or human when the device is in use together with a ferromagnetic focusing ring (16) which contains a ferroconductor metal ring and a plurality of flux focusing coils that are attached to the focusing ring and correspond in number and position to the electromagnetic bodies, each of the flux focusing coils having the same polarity as the pole of a corresponding electromagnetic body that defines one of the four vertices of the quadrilateral shape.

__________

129103			[21][11]
גן טרנסקריפטז הפוך של טלומראז, מזרז וחלבון מקודד, ערכות איבחון ותכשירי רוקחות המשתמשים בהם			TELOMERASE REVERSE TRANSCRIPTASE GENE, PROMOTER AND ENCODED PROTEIN AND DIAGNOSTIC KITS AND PHARMACEUTICAL COMPOSITIONS UTILIZING THE SAME			[54]
	01.10.1997					[22]
	US	[33]	01.10.1996	[32]	08/724643	[31]
	US		18.04.1997		08/844419
	US		25.04.1997		08/846017
	US		06.05.1997		08/851843
	US		09.05.1997		08/854050
	US		14.08.1997		08/911312
	US		14.08.1997		08/912951
	US		14.08.1997		08/915503
Int. Cl.8 A01K 067/027, A61K 038/45, C07K 016/40, C12N 001/19, 001/21, 009/12, 015/11, 015/54, 015/85, C12Q 001/48, 001/68						[51]
			UNIVERSITY TECHNOLOGY CORPORATION, U.S.A. GERON CORPORATION, U.S.A.			[71]
	WO/1998/014593					[87]
וולף, ברגמן וגולר, רחוב קרן היסוד 19ב' , ת.ד. 1352, ירושלים			WOLFF, BREGMAN AND GOLLER, 19B KEREN HAYESOD ST., P.O.B. 1352, JERUSALEM 91013			[74]

[57] A polynucleotide comprising a sequence encoding a polypeptide capable of exhibiting a telomerase catalytic activity when associated with a telomerase RNA and which is:

(a) a polynucleotide having the sequence of the insert of plasmid ATCC 209016;

or

(b) a polynucleotide which hybridizes to (a) under stringent conditions; or

(c) a polynucleotide which hybridizes to SEQ ID NO 3 or SEQ ID NO 8 under stringent conditions; or

(d) a polynucleotide sequence which is degenerate as a result of the genetic code to the sequences defined in (a) or (b).

__________

129787			[21][11]